Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
$40.9 million cash balance at the end of 2023 expected to provide cash runway into 2H 2025 Completed enrollment of Phase 2 clinical study of EQ101 in alopecia areata: topline data expected in Q2...